Company / Cash & Equivalents
Collegium Pharmaceutical, Inc. Cash & Equivalents History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$231.3M
FY2025
5-year range
$70.6M / $238.9M
FY2021-FY2025
Trend
+227.7%
vs FY2024
Sector context
#74 of 206
Health Care
What the data says
Cash & Equivalents changed +228% YoY in FY2025, a notable deviation from the 9-year average annual change of +24%.
Based on SEC 10-K filings.
$231M in FY2025 with a 5-year CAGR of +5.8%.
Declined from $239M to $231M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +10.0%
- 5-Year CAGR
- +5.8%
- 10-Year CAGR
- -
Sector benchmark
#74 of 206 in Health CareTop 36% of 206This company $231.3M Sector average $672.3M
▼
-65.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +5.8%, indicating consistent growth.
- In FY2025, cash & equivalents increased 227.7% year-over-year.
- Ranks #74 out of 206 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score 0.96 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $231.3M | +227.7% |
| FY2024 | $70.6M | -70.5% |
| FY2023 | $238.9M | +37.6% |
| FY2022 | $173.7M | -6.8% |
| FY2021 | $186.4M | +7.1% |
| FY2020 | $174.1M | +2.4% |
| FY2019 | $170.0M | +15.9% |
| FY2018 | $146.6M | +23.5% |
| FY2017 | $118.7M | -22.5% |
| FY2016 | $153.2M | +60.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026